Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

3,157 studies for “Roche”

An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid ArthritisRecruiting
NCT07620392Phase 2Updated Aug 21, 2026
Sponsor: Hoffmann-La Roche
Rheumatoid Arthritis
United States, Poland
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus NephritisRecruiting
NCT07598396Phase 2Updated Aug 21, 2026
Sponsor: Hoffmann-La Roche
Lupus · Systemic Lupus Erythematosus · Lupus Nephritis
Brazil, Colombia, Italy, Mexico, South Africa
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy ParticipantsRecruiting
NCT07271693Phase 1Updated Aug 21, 2026
Sponsor: Hoffmann-La Roche
Healthy Volunteers
New Zealand
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityCompleted
NCT07081958Phase 2Updated Aug 21, 2026
Sponsor: Hoffmann-La Roche
Obesity or Overweight
United States
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesRecruiting
NCT07177352Phase 3Updated Aug 21, 2026
Sponsor: Hoffmann-La Roche
Alzheimers Disease
United States, Argentina, Australia, Brazil, Canada +9 more
A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain InjuryRecruiting
NCT07455136N/AUpdated Aug 21, 2026
Sponsor: Hoffmann-La Roche
Traumatic Brain Injury
United States
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMDRecruiting
NCT06847542Phase 3Updated Aug 21, 2026
Sponsor: Hoffmann-La Roche
Neovascular Age-related Macular Degeneration
Austria, Czechia, Denmark, France, Germany +8 more
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid TumorsActive Not Recruiting
NCT05593094Phase 1, Phase 2Updated Aug 21, 2026
Sponsor: Hoffmann-La Roche
Advanced Solid Tumors · HER2-positive Breast Cancer
United States, Australia, France, Italy, New Zealand +2 more
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast CancerTerminated
NCT06595563Phase 2Updated Aug 20, 2026
Sponsor: Jules Bordet Institute
HER2-positive Metastatic Breast Cancer · HER2-positive Advanced Breast Cancer
Belgium, Netherlands
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative ColitisRecruiting
NCT07665723Phase 1Updated Aug 20, 2026
Sponsor: Hoffmann-La Roche
Active Ulcerative Colitis
United States, Belgium, Germany, Poland, United Kingdom
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated CancersActive Not Recruiting
NCT06496568Phase 1Updated Aug 20, 2026
Sponsor: Hoffmann-La Roche
PIK3CA-Mutated Cancers
United States, Canada, South Korea
UK SMA Patient RegistryRecruiting
NCT04292574N/AUpdated Aug 20, 2026
Sponsor: Newcastle University
Spinal Muscular Atrophy · SMA
United Kingdom
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaRecruiting
NCT04910568Phase 1Updated Aug 20, 2026
Sponsor: Genentech, Inc.
Multiple Myeloma
United States, Australia, Canada, Czechia, Denmark +8 more
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's DiseaseRecruiting
NCT06819878Phase 3Updated Aug 20, 2026
Sponsor: Hoffmann-La Roche
Moderately to Severely Active Crohns Disease
United States, Argentina, Australia, Austria, Belgium +33 more
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseRecruiting
NCT07181109Phase 3Updated Aug 19, 2026
Sponsor: Alnylam Pharmaceuticals
High Risk Cardiovascular Disease · Hypertension · High Cardiovascular Risk
United States, Argentina, Australia, Austria, Belgium +29 more
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)Active Not Recruiting
NCT05119569Phase 2Updated Aug 19, 2026
Sponsor: Hoffmann-La Roche
Relapsing Multiple Sclerosis
United States, Bosnia and Herzegovina, Croatia, Czechia, Serbia +1 more
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)Completed
NCT06624059Phase 3Updated Aug 19, 2026
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer
Australia, Brazil, Chile, China, Italy +1 more
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell LymphomaActive Not Recruiting
NCT04980222Phase 2Updated Aug 18, 2026
Sponsor: Hoffmann-La Roche
Lymphoma
United States, Denmark, France, Netherlands, Poland +1 more
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement InhibitorsActive Not Recruiting
NCT04434092Phase 3Updated Aug 18, 2026
Sponsor: Hoffmann-La Roche
Paroxysmal Nocturnal Hemoglobinuria
Argentina, Brazil, China, France, Germany +18 more
A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q SyndromeTerminated
NCT05307679Phase 2Updated Aug 18, 2026
Sponsor: Hoffmann-La Roche
Dup15q Syndrome
United States, Spain, United Kingdom
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)Recruiting
NCT07282574Phase 2Updated Aug 17, 2026
Sponsor: Hoffmann-La Roche
Progressive Multiple Sclerosis
Australia, France, Germany, Hungary, Italy +6 more
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeRecruiting
NCT07284121N/AUpdated Aug 17, 2026
Sponsor: Hoffmann-La Roche
Lung Cancer, Hepatocellular Carcinoma
Austria, Belgium, Bulgaria, Italy, Poland +3 more
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)Active Not Recruiting
NCT04546009Phase 3Updated Aug 17, 2026
Sponsor: Hoffmann-La Roche
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
United States, Argentina, Australia, Austria, Belgium +25 more
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin AmericaCompleted
NCT04158258N/AUpdated Aug 17, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
Argentina, Brazil, Chile, Colombia, Cuba +5 more
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompleted
NCT03654833Phase 2Updated Aug 17, 2026
Sponsor: University of Leicester
Mesothelioma, Malignant
United Kingdom

3,157 studies found